Clark Abbot F, Yorio Thomas
Alcon Research, Ltd, Fort Worth, Texas 76134, USA.
Nat Rev Drug Discov. 2003 Jun;2(6):448-59. doi: 10.1038/nrd1106.
Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly--age-related macular degeneration and glaucoma--will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.
数以百万计的人患有各种各样的眼部疾病,其中许多会导致不可逆转的失明。老年人不可逆转失明的主要原因——年龄相关性黄斑变性和青光眼——将随着全球人口持续老龄化而影响更多人。尽管有治疗青光眼的疗法,以及针对年龄相关性黄斑变性的治疗正在进行临床试验,但仍然非常需要更有效的治疗方法来阻止甚至逆转眼部疾病。眼睛具有特殊的特性,允许进行局部药物递送和疾病的非侵入性临床评估,但它也是一个高度复杂且独特的器官,这使得理解疾病发病机制和眼部药物研发具有挑战性。随着我们对年龄相关性黄斑变性和青光眼所涉及的细胞机制了解得更多,可能会出现新的药物靶点。本综述深入探讨了一些新的治疗方法。